臨床婦人科産科76巻10号

2022年10月発行

今月の臨床 女性医学から読み解くメタボリック症候群―専門医のための必須知識

女性ホルモンとの関係

動脈硬化に対する女性ホルモンの影響

著者： 山田容子¹

所属機関： ¹東京大学医学部附属病院老年病科

ページ範囲：P.981 - P.986

文献概要

●エストロゲンは動脈硬化に対して保護的に働く．

●閉経後は，女性も動脈硬化性疾患の発症が増加するため，閉経後の女性は男性と同じように動脈硬化のリスクマネジメントを行う必要がある

●閉経後女性に対する，脂質異常症，高血圧症，糖尿病の治療は動脈硬化性疾患の発症予防に効果がある．

参考文献

1）Kannel WB, et al : Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 155 : 57-61, 1995

2）Arai H, et al : Serum lipid survey and its recent trend in the general Japanese population in 2000. J Atheroscler Thromb 2 : 98-106, 2005

3）Lerner DJ, et al : Patterns of coronary heart disease morbidity and mortality in the sexes : a 26-year follow-up of the Framingham population. Am Heart J 111 : 383-390, 1986

4）Skafar DF, et al : Female sex hormones and cardiovascular disease in women. J Clin Endocr Metab 82 : 3913-3918, 1997

5）Nagasawa S, et al ; Evidence for Cardiovascular Prevention from Observational Cohorts in Japan（EPOCH-JAPAN）Research Group : Relation between serum total cholesterol level and cardiovascular disease stratified by sex and age group : a pooled analysis of 65 594 individuals from 10 cohort studies in Japan. J Am Heart Assoc 1 : e001974, 2012

6）Sugiyama D, et al ; NIPPON DATA 80/90 Research Group : Risk of hypercholesterolemia for cardiovascular disease and the population attributable fraction in a 24-year Japanese cohort study. J Atheroscler Thromb 22 : 95-107, 2015

7）Nakamura H, et al : MEGA Study Group ; Primary prevention of cardiovascular disease with pravastatin in Japan（MEGA Study） : a prospective randomised controlled trial. Lancet 368 : 1155-1163, 2006

8）Mizuno K, et al ; MEGA Study Group : Usefulness of pravastatin in primary prevention of cardiovascular events in women : analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese（MEGA study）. Circulation 117 : 494-502, 2008

9）Yokoyama M, et al ; Japan EPA lipid intervention study（JELIS） investigators ; Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients（JELIS） : a randomised open-label, blinded endpoint analysis. Lancet 369 : 1090-1098, 2007

10）健康日本21企画検討会，他 : 21世紀における国民健康づくり運動（健康21日本）について．健康日本21企画検討会・健康日本21計画策定検討会報告書．健康・体力づくり事業財団，2000

11）Meyer MR, et al : Obesity, insulin resistance and diabetes : sex differences and role of oestrogen receptors. Acta Physiol（Oxf） 203 : 259-269, 2011

12）Liu S, et al : Importance of extranuclear estrogen receptor-alpha and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 58 : 2292-2302, 2009

13）Peters SA, et al : Diabetes as risk factor for incident coronary heart disease in women compared with men : a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 57 : 1542-1551, 2014

14）Emerging Risk Factors Collaboration, Sarwar N, et al : Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease : a collaborative meta-analysis of 102 prospective studies. Lancet 375 : 2215-2222, 2010

15）Stampfer MJ, et al : Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 325 : 756-762, 1991

16）Hulley S, et al : Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study（HERS） Research Group. JAMA 280 : 605-613, 1998

17）Rossouw JE, et al ; writing Group for the Women's Health Initiative Investigators : Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 : 321-333, 2002

18）Rossouw JE, et al : Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 : 1465-1477, 2007

19）Hodis HN, et al : Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 374 : 1221-1231, 2016